Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism
https://doi.org/10.21518/2079-701X-2018-21-8-15
Abstract
The article discusses the issues of anticoagulant therapy in pulmonary thromboembolism. It clearly highlights the main advantages and the preferred use of direct selective oral anticoagulants represented by the thrombin inhibitor dabigatran and the factor Xa inhibitor group including apixaban, edoxaban and rivaroxaban. This article provides a thorough introduction of apixaban with an evidence base allowing to consider it a priority anticoagulant, which may be reasonably administered to the majority of patients with pulmonary thromboembolism from the first hours of the disease to many years of secondary prevention.
About the Authors
O. V. Averkov
Filatov City Clinical Hospital No.15 of the Moscow Department of Health;
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Averkov Oleg Valeryevich – Dr. of Sci. (Med.), Professor, Department of Hospital Therapy of the Medical Faculty, Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University», Ministry of Health of the Russian Federation; Deputy Chief Doctor, Head of the Regional Vascular Center of the State Budgetary Healthcare Institution of the Moscow city “Filatov City Clinical Hospital No. 15 of the Moscow Department of Health”
23 Veshnyakovskay Str., 111539, Moscow,
3 Rakhmanovsky Per., Moscow, 127994, GSP-4
V. I. Vechorko
Filatov City Clinical Hospital No.15 of the Moscow Department of Health;
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Vechorko Valery Ivanovich – Cand. of Sci. (Med.), Chief Doctor of the State Budgetary Healthcare Institution of Moscow city «Filatov City Clinical Hospital No.15 of the Moscow Department of Health»; Associate Professor, Department of Hospital Therapy, Faculty of General Medicine, Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation
23 Veshnyakovskay Str., 111539, Moscow,
3 Rakhmanovsky Per., Moscow, 127994, GSP-4
O. A. Shapsigova
Filatov City Clinical Hospital No.15 of the Moscow Department of Health
Russian Federation
Russian Federation
Shapsigova Oksana Auesovna – Cand. of Sci. (Med.), Deputy Chief Doctor for Clinical Care, Head of the State Budgetary Healthcare Institution of Moscow city
23 Veshnyakovskay Str., 111539, Moscow
References
1. Cohen A.T., Agnelli G., Anderson F.A., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756-764.
2. Klok F.A., Zondag W., van Kralingen K.W., et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med. 2010; 181: 501–506.
3. Tagalakis V., Patenaude V., Kahn S.R., Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126(832): e13–e21.
4. Strickers H. Chronic thromboembolic pulmonary hypertension – a diagnostic and therapeutic update. VASA. 2016; 45: 195–199.
5. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: Suppl: e419S-e494S.
6. Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., Cushman M., Moll S., Kessler C.M., Elliott C.G., Paulson R., Wong T., Bauer K.A., Schwartz B.A., Miletich J.P., Bounameaux H., Glynn R.J., for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 348: 1425-1434.
7. Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 349: 631-639.
8. Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406–1415.
9. Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med., 2009; 361: 2342-2352.
10. Schulman S., Kakkar A.K., Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764–772.
11. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799–808.
12. Bauersachs R., Berkowitz S.D., Brenner B., et al.. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;.363: 2499–2510.
13. Buller H.R., Prins M.H., Lensin A.W. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287–1297.
14. Prins M.H., Lensing A.W., Bauersachs R., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11: 21.
15. van der Hulle T., Kooiman J., den Exter P.L., Dekkers O.M., Klok F.A., Huisman M.V. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014; 12: 320–328.
16. Raskob G.E., Gallus A.S., Sanders P., Thompson J.R., Agnelli G., Buller H.R., Cohen A.T., Ramacciotti E., Weitz J.I. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial Thromb Haemost. 2015 Dec 10; 115(4).
17. Schulman S., Kearon C., Kakkar A.K., et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368: 709-718.
18. Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., Lensing A.W., Misselwitz F., Prins M.H., Raskob G.E., Segers A., Verhamme P., Wells P., Agnelli G., Bounameaux H., Cohen A., Davidson B.L., Piovella F., Schellong S. for the EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010; 363(26): 2499-2510.
19. Agnelli G., Buller H.R., Cohen A., et al; AMPLIFYEXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708.
20. Weitz J.I., Lensing A.W., Prins M.H., et al; for the EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017. doi: 10.1056/NEJMoa1700518.
Review
For citations:
Averkov OV, Vechorko VI, Shapsigova OA. Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism. Meditsinskiy sovet = Medical Council. 2018;(21):8-15. (In Russ.) https://doi.org/10.21518/2079-701X-2018-21-8-15
Views:
858
Email this article 